![]() |
|
|
Vol. 289, Issue 2, 791-799, May 1999
Endocrine Unit, Alcohol and Drug Abuse Research Center, McLean
Hospital-Harvard Medical School, Belmont, Massachusetts
No effective pharmacotherapy for the treatment of cocaine abuse is
currently available. In addition to pharmacological approaches, immunologic methods that use specific antibodies to bind cocaine in
blood and prevent it from reaching the central nervous system are also
being evaluated. There is considerable evidence that cocaine binds to
the dopamine transporter, and there are structural similarities between
the dopamine transporter and an anterior pituitary hormone, luteinizing
hormone (LH). These structural similarities led us to hypothesize that
LH may bind cocaine and decrease plasma levels of free cocaine.
Synthetic LH-releasing hormone (LHRH) was used to stimulate LH release
from pituitary gonadotropes before i.v. cocaine administration to male
and female rhesus monkeys. The effects of placebo-LHRH and 15 and 30 µg/kg LHRH on levels of free cocaine in plasma after i.v.
administration of 0.8 mg/kg cocaine were studied. LHRH (15 and 30 µg/kg) significantly increased LH secretion in both males
(P < .01-.001) and females (P < .01-.05). Peak plasma cocaine levels were significantly lower after
both doses of LHRH than after placebo-LHRH in males and in females
(P < .05). There was an inverse relationship
between peak plasma cocaine levels and LHRH-stimulated LH levels in
males (P < .01) but not in females.
Pharmacokinetic analyses showed that the time to reach peak plasma
cocaine levels, the elimination half-life, and the area under the
plasma cocaine curve did not differ as a function of the LHRH dose
compared with placebo LHRH. Moreover, there were no gender differences
in any cocaine-related, pharmacokinetic parameter after placebo-LHRH
administration. These data suggest the feasibility of reducing peak
levels of free cocaine in plasma by stimulating secretion of LH. The
functional consequences and underlying mechanisms of LHRH-induced
decreases in peak plasma cocaine levels remain to be determined.
This article has been cited by other articles:
![]() |
N. K. Mello, J. H. Mendelson, S. S. Negus, and M. Kelly Ovarian Steroid Hormone Modulation of the Acute Effects of Cocaine on Luteinizing Hormone and Prolactin Levels in Ovariectomized Rhesus Monkeys J. Pharmacol. Exp. Ther., January 1, 2004; 308(1): 156 - 167. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Mendelson, M. B. Sholar, A. J. Siegel, and N. K. Mello Effects of Cocaine on Luteinizing Hormone in Women during the Follicular and Luteal Phases of the Menstrual Cycle and in Men J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 972 - 979. [Abstract] [Full Text] |
||||
![]() |
N. K. Mello, J. H. Mendelson, M. Kelly, and C. A. Bowen The Effects of Cocaine on Basal and Human Chorionic Gonadotropin-Stimulated Ovarian Steroid Hormones in Female Rhesus Monkeys J. Pharmacol. Exp. Ther., September 1, 2000; 294(3): 1137 - 1145. [Abstract] [Full Text] |
||||
![]() |
B. P. Bowman, S. R. Vaughan, Q. D. Walker, S. L. Davis, P. J. Little, N. M. Scheffler, B. F. Thomas, and C. M. Kuhn Effects of Sex and Gonadectomy on Cocaine Metabolism in the Rat J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1316 - 1323. [Abstract] [Full Text] |
||||